Skip to content

Median effective dose of Ciprofol Combined with Remifentanil for Inhibiting Response to Gastroscopy in Elderly Patients

Median effective dose of Ciprofol Combined with Remifentanil for Inhibiting Response to Gastroscopy in Elderly Patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117344
Enrollment
Unknown
Registered
2026-01-22
Start date
2026-01-25
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal diseases

Interventions

A group: After the administration of remifentanil, inject the assigned dose of ciprofol within 30 seconds,the dose of ciprofol for the next patient will be determined based on the response of the pre
B group: After the administration of remifentanil, inject the assigned dose of ciprofol within 30 seconds, the dose of ciprofol for the next patient will be determined based on the response of the pr

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients over 65 years old planning to undergo painless gastroscopy under intravenous anesthesia; 2. American Society of Anesthesiologists (ASA) class I-III; 3. BMI between 18 and 28 kg/m^2; 4. Able to understand the study protocol and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Acute upper gastrointestinal bleeding with shock; 2. Known allergy to eggs, soy products, milk, or drugs such as propofol; 3. Obstructive sleep apnea; 4. Acute upper respiratory tract infection within 1 week, or asthma attack; 5. Uncontrolled severe hypertension; 6. Severe anemia; 7. Severe liver or kidney dysfunction; 8. Gastrointestinal obstruction with retention of stomach contents; 9. History of alcoholism or drug dependence.

Design outcomes

Primary

MeasureTime frame
50% Effective Dose of Ciprofol;

Secondary

MeasureTime frame
Systolic pressure;Diastolic pressure;Mean arterial pressure;Heart rate;SpO2;Induction time;Examination time;Awakening time;PACU stay time;Adverse events ;

Countries

China

Contacts

Public ContactYang Jian

The First Affiliated Hospital of Anhui Medical University

1807267528@qq.com+86 180 0402 7085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026